Athira Pharma Inc Market Cap ($26.62 Million)
Market Cap & Net Worth: Athira Pharma Inc (ATHA)
Athira Pharma Inc market cap. Athira Pharma Inc (NASDAQ:ATHA) has a market capitalization of $26.62 Million ($26.62 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #23990 globally and #5197 in its home market, demonstrating a 25.78% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Athira Pharma Inc's stock price $7.66 by its total outstanding shares 3943887 (3.94 Million). Also see ATHA operating cash flow for how efficiently the company converts equity into cash flow.
Athira Pharma Inc Market Cap History (2020–2026)
Athira Pharma Inc market cap history from 2020 to 2026. Data shows change from $135.08 Million to $30.21 Million (-13.63% CAGR). Check Athira Pharma Inc stock quote for real-time trading data and today's change.
Index Memberships
Athira Pharma Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #675 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2238 of 3165 |
Weight: Athira Pharma Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Athira Pharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Athira Pharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Athira Pharma Inc growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ATHA by Market Capitalization
Companies near Athira Pharma Inc in the global market cap rankings as of November 5, 2026. Also see Athira Pharma Inc balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Athira Pharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Athira Pharma Inc (2020–2026)
Market capitalization of Athira Pharma Inc from 2020 to today. Between 2020 and today, Athira Pharma Inc's market cap moved from $135.08 Million to $ 30.21 Million, with a yearly change of -13.63%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $30.21 Million | +1.19% |
| 2025 | $29.86 Million | +1190.27% |
| 2024 | $2.31 Million | -75.86% |
| 2023 | $9.58 Million | -23.34% |
| 2022 | $12.50 Million | -75.67% |
| 2021 | $51.39 Million | -61.96% |
| 2020 | $135.08 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Athira Pharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $26.62 Million USD |
| MoneyControl | $26.62 Million USD |
| MarketWatch | $26.62 Million USD |
| marketcap.company | $26.62 Million USD |
| Reuters | $26.62 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Athira Pharma Inc
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds… Read more